Combating Castration-Resistant Prostate Cancer by Co-Targeting the Epigenetic Regulators EZH2 and HDAC

The authors reported that combined EZH2/HDAC inhibitors potently kill castration-resistant prostate cancers (CRPCs) and caused dramatic tumor regression in aggressive human and mouse CRPC models.